Immatics Equity Warrants Exp 1 July 2025 IMTXW:NASDAQ

RT Quote | USD
Last | 05/02/24 EDT
2.51UNCH (UNCH)
Volume
1
52 week range
1.60 - 4.14
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.51
  • 52 Week High4.14
  • 52 Week High Date03/04/24
  • 52 Week Low1.60
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.51
  • 52 Week High4.14
  • 52 Week High Date03/04/24
  • 52 Week Low1.60
  • 52 Week Low Date10/25/23
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immatics Equity Warrants Exp 1 July 2025

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned...
Peter Chambre
Non-Executive Chairman of the Board
Harpreet Singh Ph.D.
Chief Executive Officer, Executive Director
Steffen Walter Ph.D.
Chief Operating Officer
Arnd Christ
Chief Financial Officer
Edward Sturchio
General Counsel
Address
Paul Ehrlich-Strasse 15
Tuebingen
72076
Germany